Related Experiment Videos
New advances in HIV entry inhibitors development.
Stefano Rusconi1, Andrea Scozzafava, Antonio Mastrolorenzo
1Instituto di Malattie Infettive e Tropicali, Universitá degli Studi di Milano, Ospedale Luigi Sacco, Milano, Italy.
Current Drug Targets. Infectious Disorders
|December 8, 2004
Summary
New antiretrovirals targeting HIV entry and fusion are advancing HIV treatment. These inhibitors, including fusion inhibitors and chemokine receptor antagonists, show promise for combination therapies and improved patient adherence.
Area of Science:
- Virology
- Pharmacology
- Immunology
Background:
- HIV utilizes cellular coreceptors (CXCR4, CCR5) for cell entry.
- Understanding HIV's entry and fusion mechanisms is crucial for developing new antiretrovirals.
- Significant progress has been made in designing inhibitors targeting these early HIV life cycle steps.
Purpose of the Study:
- To review advances in HIV entry and fusion inhibitors.
- To highlight compounds targeting gp120-CD4 interaction, chemokine receptors, and viral fusion.
- To discuss the potential of these inhibitors in combination therapies and their clinical development.
Main Methods:
- Review of scientific literature on HIV entry and fusion inhibitors.
- Identification of compounds in clinical trials targeting specific steps of HIV entry.
- Analysis of the mechanisms of action and therapeutic potential of these novel agents.
Main Results:
- Several classes of inhibitors have been developed, including gp120-CD4 inhibitors, CXCR4 antagonists, CCR5 antagonists, and fusion inhibitors.
- Compounds like enfuvirtide (T20) represent a new class of clinically approved anti-HIV agents.
- Many inhibitors demonstrate in vitro synergy with existing antiretrovirals and are progressing through clinical trials, with some offering oral formulations.
Conclusions:
- HIV entry and fusion inhibitors represent a significant advancement in antiretroviral therapy.
- These compounds offer new therapeutic strategies, including combination therapies, to combat HIV.
- The development of orally bioavailable inhibitors is key to improving patient adherence and preventing drug resistance.